Reliable in use, removable when needed – Next-gen adhesive solutions that can be precisely and residue-free removedInnovation hub with impact – Accelerating customer-specific developments...
Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech sets the global standard in contract research for biotechs...
Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech sets the global standard in contract research for biotechs...
STOCKHOLM, SWEDEN – July 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces an update from Organon on the development of the drug candidate OG-6219, acquired by Organon through its acquisition of Forendo Pharma in 2021. Following results from a Phase 2 clinical study with OG-6219, Organon plans to discontinue the clinical development of the drug candidate.
The sleep apnea market growth is driven by rising awareness, technological advancements, and demand for personalized care. Companies innovate therapies and solutions for better...
Munich, Germany – July 2, 2025 -- Ebenbuild, a company developing personalized, AI-enabled digital twins of lungs to support clinical decisions and digital clinical trials, today announced that it has received Euro 2.3 million funding under the European Innovation Council (EIC) Accelerator program to advance its digital twin platform technology. In addition, the EIC fund will invest up to €10 million in future equity financing rounds raised by Ebenbuild. The funding will support the market launch of Twinhale, the first in silico trial software built for pulmonary drug delivery. The investment also underpins Ebenbuild’s broader platform strategy to transform respiratory care through personalized lung simulation – from drug development to mechanical ventilation optimization in critical care.
New York, July 01, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, is pleased to congratulate its client, Houston American Energy Corp. (“HUSA”) , on its recent acquisition of Abundia Global Impact Group, LLC (“AGIG”). The acquisition is positioned to create a leading company focused on converting waste plastics into high-value, drop-in low-carbon fuels and chemical products.
The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....
The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....
Novo Holdings led Kate Farms' Series C financing in 2022 and supported its continued growth as the company's largest institutional investor
Transaction highlights the Planetary...
Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and...